Pioneering Precision

Cardiac Medicine

We believe to create transformative therapies, you need a commitment to a deep understanding of disease. MyoKardia is pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases.

Overview

MyoKardia’s scientists have discovered a portfolio of small molecule therapeutics aimed at the muscle proteins of the heart and intended to correct the excessive contraction, impaired relaxation or insufficient contraction underlying diseases of systolic and diastolic dysfunction. We are applying a precision medicine approach to develop our therapeutic candidates for patient populations with shared characteristics, such as causal genetic mutations or disease subtypes. Our clinical-stage pipeline includes: mavacamten (formerly MYK-461) in Phase 3 and Phase 2 clinical trials for hypertrophic cardiomyopathies (HCM); danicamtiv (formerly MYK-491) in Phase 2 for patients with stable heart failure; and MYK-224, in Phase 1 development for HCM. MyoKardia maintains global rights to all its programs.

Our leadership

Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Mr. Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis' Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co.’s vaccine division.
Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

close
William Fairey

Executive Vice President, Chief Commercial Officer

William Fairey

Executive Vice President, Chief Commercial Officer

William C. Fairey joined MyoKardia as Chief Commercial Officer and Executive Vice President in January 2019 with nearly three decades of biopharmaceutical industry experience building and leading patient-focused and science-driven organizations. Most recently, he served as the Chief Operating Officer and Executive Vice President of ChemoCentryx, Inc., where he led the company’s commercial strategy, including the development and execution of commercialization plans for avacopan and CCX140.  Prior to ChemoCentryx, Mr. Fairey held global leadership positions with Actelion Pharmaceuticals over a period of seventeen years, most recently serving as President of Actelion Pharmaceuticals U.S. Inc., overseeing more than 400 employees and $1.5 billion in net sales in 2017 before its acquisition by Johnson & Johnson for $30 billion. At Actelion US, he helped the company gain FDA approvals and launch OPSUMIT and UPTRAVI for pulmonary arterial hypertension and VALCHLOR for cutaneous T-cell lymphoma.  Mr. Fairey also served as President of Actelion Canada and as Regional Vice President of Australia Asia Pacific, where he had oversight across the region, including founding Actelion’s first affiliates in China, Taiwan and Singapore.  Before taking on the Canadian role, Mr. Fairey was Vice President of Sales and Managed Markets in the US, where he built Actelion’s first sales and managed markets teams and established the strategies and systems to support the launch of Actelion’s first product, TRACLEER.  Before joining Actelion, Mr. Fairey held a number of commercial roles during his 12 years with Parke-Davis Pharmaceuticals US.  
Mr. Fairey holds a bachelor’s degree in Biology from the University of Oregon and earned a Master of Business Administration degree from Saint Mary’s College of California. 

close
Robert McDowell, PhD

Chief Scientific Officer

Robert McDowell, PhD

Chief Scientific Officer

Robert McDowell has over three decades of experience discovering small molecule drugs in cardiovascular disease, inflammation and oncology, with seven compounds advancing into clinical trials. Dr. McDowell has been an integral part of MyoKardia since its inception in 2012, having served as Senior Vice President of Drug Discovery through October 2017, when he was promoted to his current position. Prior to joining MyoKardia, Dr. McDowell led drug discovery at 3-V Biosciences, advancing the company's lead program into development. He previously served as vice president of research at Sunesis Pharmaceuticals, where he oversaw drug discovery, translational research and manufacturing functions. Dr. McDowell led the structural chemistry group at Axys Pharmaceuticals. Before joining Axys, Dr. McDowell was a senior scientist at Genentech, where he developed successful strategies for peptidomimetic design. Dr. McDowell has authored more than 40 peer-reviewed manuscripts and is an inventor on more than 20 issued U.S. patents.
Dr. McDowell holds a B.S. in chemistry and physics from Butler University and a Ph.D. in chemistry from the University of California at Berkeley.

close
Jake Bauer

Chief Business Officer

Jake Bauer

Chief Business Officer

Jake Bauer brings more than 15 years of biopharma industry experience.  He is currently responsible for corporate and business development, program management, portfolio strategy, alliance management, and corporate strategy functions.  From July 2014 to April 2018, he also led the finance, accounting, information technology, facilities, corporate communications, and investor relations functions as senior vice president, finance and corporate development.  
He joined MyoKardia from Ablexis, LLC, where he was vice president, business operations and head of corporate development. At Ablexis, he led the development and implementation of the company’s corporate strategy and business development activities and oversaw business operations. Prior to Ablexis Mr. Bauer was a principal at Third Rock Ventures, wherehe was actively involved in a variety of leading biopharmaceutical companies including Agios, CytomX, Global Blood Therapeutics and Zafgen. Prior to Third Rock Ventures, Mr. Bauer served in roles in the investment group at Royalty Pharma, the business development group at Endo Pharmaceuticals, and was previously a management consultant at Putnam Associates.
Mr. Bauer holds a B.Sc. in biology and a B.A. in economics from Duke University and an M.B.A. from Harvard Business School. He currently serves on the board of directors of Phoenix Tissue Repair.

close
Taylor Harris

Chief Financial Officer

Taylor Harris

Chief Financial Officer

Taylor C. Harris brings more than 20 years of finance and life science industry experience to MyoKardia where he leads the finance, accounting, information technology, facilities, corporate communications and investor relations functions.
Previously, Mr. Harris most served as Senior Vice President and Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc.  During that time, he was responsible for global finance, accounting, tax, treasury, investor relations, and information technology functions, as well as the company’s commercial operations, including customer service, product support, and inside sales.  Prior to Zeltiq, Mr. Harris served as Vice President and Chief Financial Officer at Thoratec Corporation (acquired by St. Jude Medical, Inc.).  Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments.  
Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.

close
Denelle Waynick

Chief Legal Officer & Corporate Secretary

Denelle Waynick

Chief Legal Officer & Corporate Secretary

Denelle Waynick joined MyoKardia in 2020, bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life science industry. 

Ms. Waynick joined MyoKardia from UCB where she served as US General Counsel & Head of Global Enterprise Risk Management. In this role, Ms. Waynick served as the secretary and a member of the company’s US Board of Directors while also serving as a member of the US Leadership Team. During her tenure at UCB, she provided counsel to the US and global business units, including commercial operations, R&D, and regulatory. 

Prior to UCB, Ms. Waynick oversaw legal operations as Vice President, Legal Affairs, Global Brands at Actavis, Inc. (now AbbVie).  In this role, she served as part of the global brand’s executive team helping to lead the company’s strategic growth plans through product in-licensing agreements and several acquisitions.  She also served as Legal Director at Schering-Plough (now Merck) where she provided legal support to the company’s multi-million-dollar virology, respiratory and oncology product franchises.  In addition to her roles as in-house counsel, Ms. Waynick was Chief of Staff for the Office of the New Jersey Attorney General.  She began her legal career in the corporate law department of Paul Hastings in Los Angeles.  Several years later, she joined the healthcare group at Gibbons P.C., in Newark, New Jersey, where she ultimately served as Partner. 

Ms. Waynick holds a Juris Doctor degree from Howard University School of Law and received her Bachelor’s degree in Accounting from Rutgers, The State University of New Jersey-Newark.

close
Ingrid Boyes

Chief Human Resources Officer

Ingrid Boyes

Chief Human Resources Officer

Ingrid Boyes has more than 20 years of human resources and senior leadership experience across the insurance, banking and biotech industries. Prior to MyoKardia, Ms. Boyes was vice president and head of human resources for global product development at Roche. In this role, she was responsible for leading the human resources strategy globally for that function. Previously, she was at Genentech, where she held positions of increasing responsibility, including director of corporate staffing and diversity. She was also senior director of human resources for technical operations and prior to that, held a similar role leading human resources for North America commercial operations. 
Ms. Boyes holds a B.S. from the University of San Francisco and an MBA from Notre Dame de Namur University.

close
Marc Semigran, MD

Senior Vice President, Medical Sciences

Marc Semigran, MD

Senior Vice President, Medical Sciences

Marc Semigran, M.D., joined MyoKardia in December, 2016. Previously, he led the Massachusetts General Hospital Heart Failure and Cardiac Transplant Program as section head and medical director, from 2004 to 2016. In addition, he was principal investigator of the Harvard Regional Clinical Center of the National Heart, Lung, and Blood Institute Heart Failure Network. Dr. Semigran was a member of the internal medicine and cardiology staff of Massachusetts General for more than 25 years and is an associate professor at Harvard Medical School. He has published more than 140 peer-reviewed papers in cardiomyopathy, heart failure and cardiac transplantation, and served as editor for a leading textbook on heart failure. Dr. Semigran is a recipient of numerous National Institutes of Health and industry research awards, and has served as principal or co-investigator in several major clinical trials across various therapeutic areas. In addition, he has served in scientific and medical advisory capacities to such companies as GSK, Medtronic plc and Bayer.
Dr. Semigran earned A.B., A.M. and M.D. degrees from Harvard University. He completed his internal medicine residency and cardiology fellowship training at Massachusetts General.

close
Jay Edelberg, MD, PhD

Chief Medical Officer

Jay Edelberg, MD, PhD

Chief Medical Officer

Dr. Edelberg is a clinical cardiologist and vascular biologist, having served in leadership roles for two decades in both academic medicine and the biopharmaceutical industry. Most recently, Dr. Edelberg led cardiovascular drug development at Sanofi, where he spearheaded the development of Praluent® and oversaw the clinical development and global project teams involved in the MyoKardia partnership. Previously, Dr. Edelberg directed cardiovascular biomarker research at Bristol-Myers Squibb, where he served as the U.S. medical lead for Eliquis® and at Glaxo SmithKline.
From 1999 to 2006, Dr. Edelberg served as an attending coronary care unit (CCU) cardiologist and directed the Cardiac Vascular Biology Research Laboratory at Weill-Cornell Medical Center, with a specific research focus on cardiac stems cells and biomarkers of cardiac aging. Dr. Edelberg trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology). Dr. Edelberg is an M.D., Ph.D., graduate of Duke University in Durham, North Carolina. 

close
Joseph Lambing, PhD

Senior Vice President, Nonclinical & Pharmaceutical Development

Joseph Lambing, PhD

Senior Vice President, Nonclinical & Pharmaceutical Development

Joe Lambing, Ph.D., has more than 20 years of drug development experience in the areas of cardiovascular disease, inflammation and oncology. During his career, Dr. Lambing has contributed to numerous NDA and IND filings for more than a dozen new chemical entities, as well as numerous filings to support a variety of clinical trials in other countries. Prior to joining MyoKardia, he was senior vice president of development for Portola Pharmaceuticals, where he oversaw all preclinical and pharmaceutical development activities since the company’s founding in 2003. Prior to Portola, Dr. Lambing served as director of drug safety and disposition for Millennium Pharmaceuticals’ San Francisco site, and director of DMPK and toxicology at COR Therapeutics.
Dr. Lambing holds a B.S. in chemistry and a Ph.D. in biochemistry from the University of Missouri, and was a postdoctoral fellow at the University of California, San Diego.

close
Barbara Troupin, MD, MBA

Senior Vice President, Medical Affairs

Barbara Troupin, MD, MBA

Senior Vice President, Medical Affairs

Dr. Troupin has more than 20 years of pharmaceutical industry leadership experience across Medical Affairs, Clinical Development, and Regulatory Affairs in small, private and publicly traded pharmaceutical companies in the U.S. and Europe. In her current role as Senior Vice President Medical Affairs, Dr. Troupin is focused on building out the Medical Affairs functions to drive towards and support a successful launch for mavacamten as well as initiating further landscape development across the portfolio.

Previously, she served as Chief Medical Officer at ERX Pharmaceuticals, a small, virtual drug development start-up in the metabolic space. Prior to that she served as CMO and VP Clinical Development & Regulatory Affairs at Aquinox Pharmaceuticals and SVP Clinical Development and CMO at Apricus Biosciences. Prior to that, while at VIVUS, she held roles in Clinical Development and subsequently Medical Affairs, leading clinical and medical teams in the development, approval, and launch of Qsymia for the treatment of obesity. Dr. Troupin has been a key member of the leadership team for 3 NDAs, 2 MAAs, and a U.S.-focus launch, as well as assuring alignment of partner and European launches. She has strategic leadership experience in building and growing teams, departments and companies, pipeline optimization, regulatory affairs and label negotiation, partnering and fundraising, and key stakeholder relationship nurturing. Dr. Troupin completed her medical degree at the University of Pennsylvania, her M.B.A. at The Wharton School of Business both in Philadelphia, and Family Medicine Residency in San Diego.  

close
Holly Schachner, MD

Senior Vice President, Therapeutic Area

Holly Schachner, MD

Senior Vice President, Therapeutic Area

Dr. Schachner joined Myokardia in September 2020. She has extensive experience in medical affairs and late stage clinical development across a range of therapeutic and device areas. Holly has driven transformative changes to create strategic global medical teams that have launched new therapies and developed innovative approaches for clinical endpoint and outcome studies. Her teams have won prestigious awards from the Academy of Interactive & Visual Arts for their innovation and impact.

Most recently, Holly was Chief Medical Officer, Global Specialty Medicine at Allergan, where she led the transformation to a matrixed medical organization across multiple therapeutic areas in phase 1 through phase 4, including CV, GI, Immunology, Women’s Health and Anti-Infectives.  Holly also served as Co-Head of Medical and Safety COVID-19 Task Force at Allergan, leading a cross functional team to create and implement governance measures across the global business. 

Prior to Allergan, Holly was at Sanofi, where she was the North America Medical Head for the Diabetes Cardiovascular Business Unit and served as U.S. Medical Chair across all business units. As the NA medical head, she led launch preparedness for several pipeline products. As the US Medical Chair, Holly met with stakeholders on Capitol Hill to gather insights on patient and healthcare system needs. Holly served on the Board of Directors of the Sanofi Foundation for North America, which oversaw disaster relief, corporate social responsibility initiatives, and patient assistance programs. 

Earlier in her career, Holly held medical leadership positions at Bayer Diabetes Care, Pfizer, Inc., and at Columbia University, where she created and led a highly regarded, multi-disciplinary Pediatric Diabetes team that provided care to patients diagnosed with type 1 diabetes, type 2 diabetes, and obesity. 

Holly holds a Doctor of Medicine (MD) degree from the State University of New York, Stony Brook and a Bachelor of Arts in Psychology from the University of Michigan. She completed her Pediatric Residency and Pediatric Endocrinology Fellowship at Mount Sinai Medical Center in New York City.  She is a Diplomate of the National Board of Medical Examiners and American Boards of Pediatrics and Pediatric Endocrinology. She previously served on the board of the Juvenile Diabetes Research Foundation New York Chapter.   

close
Willem van Weperen

Senior Vice President, Head of Europe

Willem van Weperen

Senior Vice President, Head of Europe

Mr. van Weperen joined Myokardia in February 2020, to develop a European commercial strategy and to build the organization & infrastructure to launch mavacamten in Europe. 
Willem has more than 25 years of experience in the biopharmaceutical industry. During this period he was active in the areas of R&D and commercialization, and fulfilled several leadership positions. In these roles he successfully contributed to bring therapies to patients with rare diseases and to build healthcare systems to provide optimal care.
Willem started his career in clinical research at GSK in 1993 in the neurology area. In 1994 he joined Genzyme, where he fulfilled several medical and commercial positions. This included leadership roles for Global Marketing in the rare genetic disease business unit and as General Manager for Genzyme Netherlands. In 2009 Willem joined the biotech start-up company to-BBB as their CEO. With his team he brought two brain disease therapies in the clinic, raised capital in equity and grants, and established several collaborations with pharma companies. In 2014 Willem served as Chief Commercial Officer of Prosensa Holding N.V. (acquired by BioMarin) and prepared the global launch of a therapy for patients with Duchenne Muscular Dystrophy. 
Most recently (2015-2019) Willem served as Regional Vice President International for Amicus Therapeutics. In this role he supported the establishment of a commercial infrastructure and the development of launch strategies for Fabry disease therapy Galafold, first in several European countries, followed by Middle East, Asia and Latin America. 
Willem obtained a MSc degree in biomedical sciences from Utrecht University, and an Executive MBA degree from NIMBAS / Bradford University.

close

Our Board of Directors

Sunil Agarwal, MD

Independent Director

Sunil Agarwal, MD

Independent Director

Sunil Agarwal, M.D., is president of research and development at Juno Therapeutics. Previously, he was a partner in Sofinnova, a Menlo Park, Ca. based biotech-focused investment firm. He is also a former executive vice president and chief medical officer for Ultragenyx Pharmaceutical, where he managed the company's clinical development and operations, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology and toxicology. Dr. Agarwal served in various leadership roles at Genentech for more than a decade, including senior vice president and global head of clinical development for ophthalmology, metabolism, neurosciences, immunology and infectious diseases. He led the approval of multiple therapies at Genentech including RITUXAN®, ACTEMRA®, LUCENTIS® and XOLAIR®. Earlier in his career, Dr. Agarwal was at MedImmune and Guilford Pharmaceuticals, where he served in both development and medical affairs, and led the formation of the medical affairs organization for Guilford. He completed his residency at Children’s National Medical Center (CNMC), Washington, D.C., and practiced in the CNMC Pediatric Emergency Department. He has served on the faculty at George Washington University School of Medicine as Assistant Clinical Professor of Pediatrics.
Dr. Agarwal obtained a B.S. in neurobiology at Cornell University, and earned his M.D. from Tufts University School of Medicine.

close
Mary Cranston

Independent Director

Mary Cranston

Independent Director

Mary Cranston joined MyoKardia as an independent director in April 2016. Ms. Cranston is a retired senior partner of Pillsbury Winthrop Pittman LLP, an international law firm. She was formerly chair and chief executive officer of Pillsbury.
Ms. Cranston currently serves as a director of Visa Inc., The Chemours Company and CSAA Insurance. She is also the chair of the board of the Stanford Children's Hospital and Children's Health Network. She previously served as a member of the boards of Juniper Networks, International Rectifier Corporation, Exponent, Inc. and GrafTech International, Inc., and is a former member of the Stanford University Board of Trustees. Ms. Cranston has been recognized by the National Law Journal as one of the 100 Most Influential Lawyers in America.
Ms. Cranston holds both A.B. and J.D. degrees from Stanford University.

close
Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos

Chief Executive Officer

Tassos Gianakakos joined MyoKardia in October 2013, bringing more than 17 years of senior leadership experience and business development and finance expertise in the biopharmaceutical industry to the company. He joined MyoKardia from MAP Pharmaceuticals (acquired by Allergan in March 2013), where he was most recently senior vice president and chief business officer. In this position, Mr. Gianakakos played an integral role in advancing the company’s two Phase 3 clinical programs and regulatory filings for LEVADEX®, and led the successful co-promotion partnership agreement for the program with Allergan, as well as a global partnership with AstraZeneca for the company’s Unit Dose Budesonide program. Prior to MAP, Mr. Gianakakos led the formation of Codexis, Inc., a spin-off of Maxygen, Inc., in 2001. At Codexis, Mr. Gianakakos served as president and senior vice president, business development, and global head of Codexis' Pharmaceuticals Business Unit. Before forming Codexis, Mr. Gianakakos was director of business development at Maxygen, where he led the company’s business development efforts for its vaccine and bio-industrial platforms, as well as financing activities including the company’s initial public offering. Prior to Maxygen, Mr. Gianakakos was a process engineer in Merck & Co.’s vaccine division.
Mr. Gianakakos holds B.Sc. degrees in chemical engineering and economics from the Massachusetts Institute of Technology, an M.Sc. in biotechnology from Northwestern University and an M.B.A. from Harvard Business School.

close
David Meeker, M.D.

Independent Director

David Meeker, M.D.

Independent Director

Dr. David Meeker is President and Chief Executive Officer of Rhythm Pharmaceuticals, Inc., a pharmaceutical company that is focused on the research of rare genetic disorders of obesity caused by an impaired pathway in the brain that regulates hunger. Most recently, he served as President and CEO of KSQ Therapeutics for approximately three years. Previously, David was the Executive Vice President and Head of Sanofi Genzyme, the specialty-care global business unit of Sanofi that focused on rare diseases, multiple sclerosis, oncology and immunology. He joined Genzyme in 1994 as Medical Director and, over the course of his tenure, served the company as Vice President of Medical Affairs, Chief Operating Officer, and Chief Executive Officer. He led Genzyme’s commercial organization and global market access functions and managed the launch of several treatments for rare genetic diseases, including Aldurazyme®, Fabrazyme® and Myozyme®. Prior to his tenure with Genzyme, David was Director of the Pulmonary Critical Care Fellowship at the Cleveland Clinic and an Assistant Professor of Medicine at Ohio State University. Dr. Meeker received his M.D. degree from the University of Vermont Medical School. He completed the Advanced Management Program at Harvard Business School in 2000.

close
Mark Perry

Independent Director

Mark Perry

Independent Director

Mark Perry is a biotech veteran with more than 30 years of industry experience. Mr. Perry has served as an entrepreneur-in-residence at Third Rock Ventures and as president, chief executive officer and director of Aerovance, Inc., a biotechnology company focused on the development of human therapeutics for respiratory and allergic diseases. From 1994 to 2007, Mr. Perry served in several executive roles at Gilead Sciences, Inc., including executive vice president of operations, as well as general counsel and chief financial officer. Earlier in his career, Mr. Perry was a partner of Cooley LLP, where he maintained a corporate and securities practice with an emphasis on biotechnology and high technology companies, investment banks and venture capital partnerships. He currently serves as chairman of the board of Global Blood Therapeutics and director of Nvidia Corporation. Mr. Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards.
Mr. Perry holds a B.A. from the University of California, Berkeley and a J.D. from the University of California, Davis.

close
Kim Popovits

Independent Director

Kim Popovits

Independent Director

Kim Popovits has been widely recognized for her contributions to science and the commercialization of the biotechnology industry. Ms. Popovits has been Genomic Health’s chairman of the board since 2012, and chief executive officer and president since 2009. She served as president and chief operating officer since joining the company in 2002. Previously, Ms. Popovits spent 15 years at Genentech, where she led the successful commercialization of 14 new therapies. Before joining Genentech, Ms. Popovits served as division manager for American Critical Care, a division of American Hospital Supply Corporation. She currently serves on the boards of American Clinical Laboratory Association, California Life Sciences Association, Personalized Medicine Coalition, and ZS Pharma. She is president of The Coalition for 21st Century Medicine and serves as an advisor to the Healthcare Businesswomen’s Association. 
Ms. Popovits holds a B.A. degree in business from Michigan State University.

close
Wendy Yarno

Independent Director

Wendy Yarno

Independent Director

Wendy Yarno held positions of increasing responsibility over a 26-year career at Merck & Co, Inc., leading multiple business groups. Most recently, she served as chief marketing officer, leading the global organization charged with all aspects of pre-and post-launch commercialization of pharmaceuticals in more than 20 therapeutic areas. Ms. Yarno also served as Merck’s senior vice president of human resources, where her successful efforts to develop and implement new corporate HR strategies proved transformative for this key business function. Previously, Ms. Yarno was vice president of the Johnson & Johnson Co. unit Ortho McNeil Pharmaceutical’s highly profitable Women’s Health Care Franchise. Ms. Yarno has served on the boards of ADial Pharmaceuticals, Durata Therapeutics, Medivation, St. Jude Medical, and PluroGen Therapeutics.
Ms. Yarno received an M.B.A. from the Fox School of Business at Temple University and a B.S. in business administration from Portland State University.

close

Our History

MyoKardia was founded in 2012 by Third Rock Ventures and four scientific leaders in their respective fields, Leslie Leinwand, PhD, at the BioFrontiers Institute at the University of Colorado, Christine Seidman, MD, with Harvard Medical School and Brigham and Women’s Hospital, Jonathan Seidman, PhD, also from Harvard Medical School, and James Spudich, PhD, with Stanford University.

Together, they shared a vision that there was a lack of therapeutic innovation in treating cardiovascular disease – the number one cause of death globally. Leveraging their diverse expertise in company formation, myosin motors and heart muscle function, and genetics, MyoKardia was formed to discover and develop novel therapeutics that could address the underlying biomechanical cause of disease for well-defined patient populations.

Timeline of MyoKardia's Corporate History

what's happening

Life at MyoKardia